EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers

Khine S Shan iD, Amalia Bonano-Rios iD, Nyein Wint Yee Theik, Atif Hussein, Marcelo Blaya

International Journal of Molecular Sciences · 06.02.2024 · 25 (4) · 1973

DOI: 10.3390/ijms25041973 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.02.2024. Verfasst von Khine S Shan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Memorial Health Care, Pembroke Pines, FL 33028, USA. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 268 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The dysregulation of the phosphatidylinositol-3-kinase (PI3K) pathway can lead to uncontrolled cellular growth and tumorigenesis. Targeting PI3K and its downstream substrates has been shown to be effective in preclinical studies and phase III trials with the approval of several PI3K pathway inhibitors by the Food and Drug Administration (FDA) over the past decade. However, the limited clinical efficacy of these inhibitors, intolerable toxicities, and acquired resistances limit the clinical application of PI3K inhibitors. This review discusses the PI3K signaling pathway, alterations in the PI3K pathway causing carcinogenesis, current and novel PI3K pathway inhibitors, adverse effects, resistance mechanisms, challenging issues, and future directions of PI3K pathway inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsHumansPhosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesTOR Serine-Threonine KinasesMolecular Targeted TherapyProto-Oncogene Proteins c-aktPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsCarcinogenesisPhosphatidylinositols

Stichwörter der Autor:innen

AKTPI3KmTORmolecular profilingpersonalized medicinephosphatidylinositol-3-kinasetargeted therapy

Substanzen

Phosphatidylinositol 3-KinasePhosphatidylinositol 3-KinasesTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsPhosphatidylinositolsAntineoplastic Agents

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Memorial Health Care, Pembroke Pines, FL 33028, USA.
  • Division of Internal Medicine, Memorial Health Care, Pembroke Pines, FL 33028, USA.

ORCID-Profile: Khine S Shan, Amalia Bonano-Rios

Zitieren

APA

Shan, K. S., Bonano-Rios, A., Theik, N. W. Y., Hussein, A., & Blaya, M. (2024). Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers. International Journal of Molecular Sciences, 25(4), 1973. https://doi.org/10.3390/ijms25041973

Vancouver

Shan KS, Bonano-Rios A, Theik NWY, Hussein A, Blaya M. Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers. International Journal of Molecular Sciences. 2024;25(4):1973. doi:10.3390/ijms25041973

BibTeX
@article{Shan2024,
  author = {Shan, Khine S and Bonano-Rios, Amalia and Theik, Nyein Wint Yee and Hussein, Atif and Blaya, Marcelo},
  title = {Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {4},
  pages = {1973},
  doi = {10.3390/ijms25041973}
}
Kostenlos starten →